Navigation Links
Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine),Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that its Phase 2 multi-dose study of Rylomine was published in Pain Medicine, the official journal of The American Academy of Pain Medicine. The article, entitled, "Analgesic Efficacy and Safety of Morphine-Chitosan Nasal Solution in Patients with Moderate to Severe Pain Following Orthopedic Surgery", was recently made available online and can found at the following link: http://www.blackwell-synergy.com/toc/pme/0/0?.

"Rylomine is one of three late stage drug development candidates in our pipeline that address large underserved markets for pain management. It employs a patented formulation of intranasal morphine in a simple disposable device that requires no programming or special patient education," said, Dr. Daniel B. Carr, CEO and CMO. "While still in development, Rylomine has potential to become the non-invasive approach of choice for administering intermittent doses of morphine for post-surgical pain in medically supervised settings. Morphine is the reference standard for treatment of post-surgical pain, as well as pain from trauma and diseases including cancer."

Top line data from the first of two pivotal post-surgical Phase 3 clinical trials of Javelin's Rylomine is anticipated this summer.

Orthopedic Surgeries

According to the United States Department of Health and Human Services, orthopedic operations make up approximately 10% (7.4 million) of the 73.4 million ambulatory and in-patient surgical procedures in the United States annually.

About Rylomine

Rylomine (intranasal morphine), is currently in Phase 3 development in the United States, for moderate-to-severe pain in supervised healthcare settings. It employs the patented and proprietary, Chysis(R) drug-delivery platform to adhere and regularize the kinet
'"/>




Page: 1 2 3

Related medicine technology :

1. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/4/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("HMP"), its drug R&D subsidiary, successfully achieved the ... of fruquintinib in patients with advanced non-squamous non-small ... .  The top-line results demonstrated that the ... endpoint of progression free survival ("PFS"). ...
(Date:9/3/2015)... With a population of more than 1 ... also its single largest potential market for goods and ... all major world economies in the average rate of ... health expenditures. As an in vitro diagnostics (IVD) market, ... United States, western European countries, and Japan. China represents ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2
... 15, 2012 For the 35 million people ... new, fast, effective approach to treatment is now ... light, radiofrequency and ultrasound aesthetic and medical devices, ... newest innovation for the Harmony(XL) multi-application, multi-technology platform, ...
... BARCELONA, Spain, March 15, 2012 Grifols (MCE:GRF, MCE:GRF.P ... largest plasma product manufacturer and a pioneer in the ... to both scientific and social development, has acquired 51% ... the viability of its projects and the future of ...
Cached Medicine Technology:New Nail Fungus Approach Receives FDA Clearance 2Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 2Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 3Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 4Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 5Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 6Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 7Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 8
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law ... De La Paz. , Schmidt National Law Group, a leading firm in mass-tort ... California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for six ... apparel. In an effort to assist the team, the Jones Agency, a locally owned ... to raise funds for the new uniforms. , As is so often the case ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Keeping mold ... and around the home is quite common. Mold can grow anywhere - on carpet, ... leaking pipes. Checking for excessive moisture and water in the home is key to ...
(Date:9/4/2015)... ... 04, 2015 , ... Many consumers are looking for a quick and convenient way to produce ... patent-pending K Med Cups provide a quick and simple way to brew a hot cup ... or cough. As a result, they enhance comfort and health. The invention features a novel ...
(Date:9/4/2015)... ... ... Having access to a doctor can sometimes be a challenge for a variety ... visits which affects hospitals’ abilities to provide quality service to those with serious needs, ... this problem has recently presented itself, the new telemedicine platform and app, DocChat ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3
... Year End,2007 Earnings Webcast and Conference Call event:, ... 2007 Earnings Webcast and Conference Call March 31, ... Webcast and Conference Call event, please enter, http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2167880 ... conference call please dial into either,(604) 677-8677 or (800) ...
... announced today,that it has initiated coverage on leading Australian ... hand and royalty,revenue alone are equal to roughly US$0.94 ... DCF value for ART621 and you have a premium,of ... without assigning any,value to their current pre-clinical pipeline which ...
... Md., March 18 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... of,Directors has unanimously approved a three-for-two split of all ... share, including its Class,B Common Stock. Stockholders of record ... will receive one-half additional share of Common Stock for ...
... full Senate, moves to House, PHOENIX, March 18 ... Medicaid program to expend moneys to provide,smoking cessation treatments ... of 27 to 3., Currently, Arizona is one ... programs in the state,s Medicaid program, which in,Arizona is ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
... -- For years, scientists have been proclaiming the benefits ... health have exploded in number, examining many health problems ... death. , Now, a University of Missouri researcher ... the Centers for Disease Control that a reduction in ...
Cached Medicine News:Health News:Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx) 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2Health News:Killer stairs? Taking the elevator could be worse for your body 2Health News:Killer stairs? Taking the elevator could be worse for your body 3
... System simplifies the process of separating proteins and ... able to run four gels at a time, ... and throughput, the 120 mini-vertical runs up to ... L) at one time. The 120 mini-vertical has ...
... 48 gels run in the specially ... the base and power supply in ... power supply contains an electrical plug ... an electrical outlet and is used ...
... designed with a spring-loaded mechanism to ensure ... gel cassettes stay firmly in place during ... loading from one gel to the next ... robot loading software. In addition, the E-Holder™ ...
... The Classic Series gel tanks come ... gasketed gel trays, making gel pouring as ... give you total felxibility in your application. ... the small 7 x 8cm gel size ...
Medicine Products: